<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04917861</url>
  </required_header>
  <id_info>
    <org_study_id>mRNA-1893-P201</org_study_id>
    <nct_id>NCT04917861</nct_id>
  </id_info>
  <brief_title>A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas</brief_title>
  <official_title>A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose Confirmation Study to Evaluate the Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Adults Aged 18 Through 65 Years and Living in Endemic and Non-Endemic Flavivirus Areas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ModernaTX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ModernaTX, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study will evaluate the safety, tolerability and reactogenicity of 2 dose&#xD;
      levels of mRNA 1893 Zika vaccine in comparison to a placebo control in healthy participants&#xD;
      who are flavivirus-seronegative and in participants who are flavivirus-seropositive.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2021</start_date>
  <completion_date type="Anticipated">September 17, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 17, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Solicited Local and Systemic Adverse Reactions (ARs)</measure>
    <time_frame>Up to Day 36 (7 days after each vaccination)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Up to Day 57 (28 days after each vaccination)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Medically Attended Adverse Events (MAAEs)</measure>
    <time_frame>Day 1 throughout the entire study duration (up to Day 700)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Serious Adverse Events (SAEs) and Adverse Events of Special Interests (AESIs)</measure>
    <time_frame>Day 1 throughout the entire study duration (up to Day 700)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) of Zika Virus (ZIKV)-Specific Neutralizing Antibodies (nAb) in All Participants, Initially Flavivirus Seronegative, and Initially Flavivirus Seropositive Participants, as Measured by Plaque Reduction Neutralization Test (PRNT)</measure>
    <time_frame>Day 57</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Seroconversion, as Measured by PRNT</measure>
    <time_frame>Day 1 to Day 57</time_frame>
    <description>Seroconversion is defined as either an increase in ZIKV-specific nAb titer from below the lower limit of quantification (LLOQ) to a titer equal to or above LLOQ, or an increase of at least 4-fold in ZIKV-specific nAb titer in participants with pre-existing nAb titers (as measured by PRNT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GMT of ZIKV-Specific nAbs in All Participants, as Measured by PRNT</measure>
    <time_frame>Days 1, 8, 29, and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of ZIKV-Specific nAbs in All Participants, as Measured by Microneutralization (MN)</measure>
    <time_frame>Days 1, 8, 29, 36 and 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of ZIKV-Specific nAbs in Initially Flavivirus Seronegative Participants, as Measured by PRNT</measure>
    <time_frame>Days 1, 8, 29, and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of ZIKV-Specific nAbs in Initially Flavivirus Seronegative Participants, as Measured by MN</measure>
    <time_frame>Days 1, 8, 29, 36, and 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of ZIKV-Specific nAbs in Initially Flavivirus Seropositive Participants, as Measured by PRNT</measure>
    <time_frame>Days 1, 8, 29, and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of ZIKV-Specific nAbs in Initially Flavivirus Seropositive Participants, as Measured by MN</measure>
    <time_frame>Days 1, 8, 29, 36, and 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold-Rise (GMFR) of ZIKV-Specific nAbs in All Participants, as Measured by PRNT</measure>
    <time_frame>Days 8, 29, 36, and 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR of ZIKV-Specific nAbs in All Participants, as Measured by MN</measure>
    <time_frame>Days 8, 29, 36, and 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR of ZIKV-Specific nAbs in Initially Flavivirus Seronegative Participants and Initially Flavivirus Seropositive Participants, as Measured by PRNT</measure>
    <time_frame>Days 8, 29, and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR of ZIKV-Specific nAbs in Initially Flavivirus Seronegative Participants and Initially Flavivirus Seropositive Participants, as Measured by MN</measure>
    <time_frame>Days 8, 29, 36, and 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion, as Measured by PRNT</measure>
    <time_frame>Day 1 to Days 8, 29, and 36</time_frame>
    <description>Seroconversion is defined as either an increase in ZIKV-specific nAb titer from below the LLOQ to a titer equal to or above LLOQ, or an increase of at least 4-fold in ZIKV-specific nAb titer in participants with pre-existing nAb titers (as measured by PRNT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion, as Measured by MN</measure>
    <time_frame>Day 1 to Days 8, 29, 36, and 57</time_frame>
    <description>Seroconversion is defined as either an increase in ZIKV-specific nAb titer from below the LLOQ to a titer equal to or above LLOQ, or an increase of at least 4-fold in ZIKV-specific nAb titer in participants with pre-existing nAb titers (as measured by MN).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Initially Seronegative Participants With a Seroresponse, as Measured by PRNT</measure>
    <time_frame>Days 8, 29, and 36</time_frame>
    <description>Seroresponse is defined as an increase in ZIKV-specific nAb titer (as measured by PRNT) from below the LLOQ to greater than or equal to the LLOQ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Initially Seronegative Participants With a Seroresponse, as Measured by MN</measure>
    <time_frame>Days 8, 29, 36, and 57</time_frame>
    <description>Seroresponse is defined as an increase in ZIKV-specific nAb titer (as measured by MN) from below the LLOQ to greater than or equal to the LLOQ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Initially Seropositive Participants With a 2-Fold or 4-Fold Increase in ZIKV-Specific nAb Titers as Compared With Baseline, as Measured by PRNT</measure>
    <time_frame>Days 8, 29, and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Initially Seropositive Participants With a 2-Fold or 4-Fold Increase in ZIKV-Specific nAb Titers as Compared With Baseline, as Measured by MN</measure>
    <time_frame>Days 8, 29, 36, and 57</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Zika Virus</condition>
  <arm_group>
    <arm_group_label>mRNA-1893 Low Dose (2-Dose Regimen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day (-3/+7 days) interval between vaccinations (administered on Day 1 and Day 29).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mRNA-1893 High Dose (2-Dose Regimen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day (-3/+7 days) interval between vaccinations (administered on Day 1 and Day 29).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mRNA-1893 High Dose (1-Dose Regimen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive placebo matching to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There will be 28-day (-3/+7 days) interval between vaccinations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo matching to mRNA-1893 administered as a 2-dose regimen with 28-day (-3/+7 days) interval between vaccinations (administered on Day 1 and Day 29).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA-1893</intervention_name>
    <description>Solution for injection</description>
    <arm_group_label>mRNA-1893 High Dose (1-Dose Regimen)</arm_group_label>
    <arm_group_label>mRNA-1893 High Dose (2-Dose Regimen)</arm_group_label>
    <arm_group_label>mRNA-1893 Low Dose (2-Dose Regimen)</arm_group_label>
    <other_name>Zika vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% sodium chloride solution for injection</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>mRNA-1893 High Dose (1-Dose Regimen)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Understands and agrees to comply with the study procedures and provides written&#xD;
             informed consent.&#xD;
&#xD;
          -  According to investigator assessment, is in good general health and can comply with&#xD;
             study procedures.&#xD;
&#xD;
          -  Female participants of childbearing potential may be enrolled in the study if the&#xD;
             participant: has a negative pregnancy test at the Eligibility Visit and on the day of&#xD;
             the first investigational product (IP) injection; has practiced adequate contraception&#xD;
             or has abstained from all activities that could result in pregnancy for at least 28&#xD;
             days prior to the first IP injection; has agreed to continue adequate contraception&#xD;
             through 3 months following the last IP injection; and is not currently breastfeeding.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Participant is acutely ill or febrile (temperature ≥38.0°Celsius/100.4°Farenheight) on&#xD;
             the day of the first or second vaccination.&#xD;
&#xD;
          -  Participant had prior administration of a ZIKV vaccine candidate during a clinical&#xD;
             study investigation.&#xD;
&#xD;
          -  Participant had prior administration of a marketed dengue vaccine or dengue vaccine&#xD;
             candidate under clinical study investigation.&#xD;
&#xD;
          -  Participant has a body mass index (BMI) from ≤18 or ≥35 kilograms (kg)/square meter&#xD;
             (m^2).&#xD;
&#xD;
          -  Participant has a medical, psychiatric, or occupational condition that may pose&#xD;
             additional risk as a result of participation or that could interfere with safety&#xD;
             assessments or interpretation of results.&#xD;
&#xD;
          -  Participant has as a history of anaphylaxis, urticaria, or other significant AR&#xD;
             requiring medical intervention after receipt of a vaccine, including an mRNA vaccine&#xD;
             or any components of an mRNA vaccine.&#xD;
&#xD;
          -  Participant has received or plans to receive a vaccine ≤28 days prior to the first IP&#xD;
             injection or plans to receive a nonstudy vaccine within 28 days prior to or after any&#xD;
             IP injection. Licensed influenza vaccine received within 14 days prior to the first IP&#xD;
             injection or plans to receive a licensed influenza vaccine 14 days prior to through 14&#xD;
             days following each IP injection are not exclusionary. Any COVID-19 vaccine&#xD;
             (regardless of type of vaccine) that becomes available to participant during the study&#xD;
             is not exclusionary; efforts should be made to space IP injections and COVID-19&#xD;
             vaccinations by at least 7 days and preferably 14 days, but COVID-19 vaccinations&#xD;
             should not be delayed.&#xD;
&#xD;
          -  Participant has received systemic immunoglobulins or blood products within 3 months&#xD;
             prior to the day of enrollment.&#xD;
&#xD;
          -  Participant has donated ≥450 milliliters (mL) of blood products within 28 days of the&#xD;
             Day 1 Visit.&#xD;
&#xD;
          -  Participant has participated in an interventional clinical study within 28 days prior&#xD;
             to the day of enrollment or plans to do so while enrolled in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Moderna Clinical Trials</last_name>
    <phone>877-913-3286</phone>
    <email>clinicaltrials@modernatx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Meridian Clinical Research (Sioux City, IA)</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johnson County Clin-Trials</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Benchmark Research - Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Puerto Rico, Inc.</name>
      <address>
        <city>Guayama</city>
        <zip>00784</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ponce Medical School Foundation, Inc.</name>
      <address>
        <city>Ponce</city>
        <zip>00713</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ponce Medical School Foundation, Inc.</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Puerto Rico, Inc.</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Latin Clinical Trial Center, Inc.</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>GCM Medical Group, PSC</name>
      <address>
        <city>San Juan</city>
        <zip>00917</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carribean Medical Research</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Flavivirus</keyword>
  <keyword>mRNA-1893</keyword>
  <keyword>Zika vaccine</keyword>
  <keyword>Moderna</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zika Virus Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

